메뉴 건너뛰기




Volumn 7, Issue 40, 2016, Pages 66192-66201

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

Author keywords

Breast cancer; Cytotoxic T lymphocytes; HER2; Trastuzumab; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GP2 VACCINE; TRASTUZUMAB; UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE FRAGMENT; SUBUNIT VACCINE;

EID: 84994173070     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11751     Document Type: Article
Times cited : (86)

References (20)
  • 1
    • 84906847366 scopus 로고    scopus 로고
    • Final Report of the Phase I/II Clinical Trial of the E75 (nelipepimut-S) Vaccine with Booster Inoculations to Prevent Disease Recurrence in High-Risk Breast Cancer Patients
    • Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S and Peoples GE. Final Report of the Phase I/II Clinical Trial of the E75 (nelipepimut-S) Vaccine with Booster Inoculations to Prevent Disease Recurrence in High-Risk Breast Cancer Patients. Ann Oncol. 2014; 25:1735-1742.
    • (2014) Ann Oncol , vol.25 , pp. 1735-1742
    • Mittendorf, E.A.1    Clifton, G.T.2    Holmes, J.P.3    Schneble, E.4    van Echo, D.5    Ponniah, S.6    Peoples, G.E.7
  • 2
    • 0029555751 scopus 로고
    • Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction
    • Fisk B, Savary C, Hudson JM, O'Brian CA, Murray JL, Wharton JT and Ioannides CG. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother Emphasis Tumor Immunol. 1995; 18:197-209.
    • (1995) J Immunother Emphasis Tumor Immunol , vol.18 , pp. 197-209
    • Fisk, B.1    Savary, C.2    Hudson, J.M.3    O'Brian, C.A.4    Murray, J.L.5    Wharton, J.T.6    Ioannides, C.G.7
  • 4
    • 0033579435 scopus 로고    scopus 로고
    • Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide
    • Kuhns JJ, Batalia MA, Yan S and Collins EJ. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem. 1999; 274:36422-36427.
    • (1999) J Biol Chem , vol.274 , pp. 36422-36427
    • Kuhns, J.J.1    Batalia, M.A.2    Yan, S.3    Collins, E.J.4
  • 5
    • 0034331218 scopus 로고    scopus 로고
    • Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
    • Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96:3102-3108.
    • (2000) Blood , vol.96 , pp. 3102-3108
    • Brossart, P.1    Wirths, S.2    Stuhler, G.3    Reichardt, V.L.4    Kanz, L.5    Brugger, W.6
  • 7
    • 75649136936 scopus 로고    scopus 로고
    • Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
    • Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S and Peoples GE. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010; 116:292-301.
    • (2010) Cancer , vol.116 , pp. 292-301
    • Carmichael, M.G.1    Benavides, L.C.2    Holmes, J.P.3    Gates, J.D.4    Mittendorf, E.A.5    Ponniah, S.6    Peoples, G.E.7
  • 9
    • 84860700518 scopus 로고    scopus 로고
    • Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    • Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S and Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012; 118:2594-2602.
    • (2012) Cancer , vol.118 , pp. 2594-2602
    • Mittendorf, E.A.1    Clifton, G.T.2    Holmes, J.P.3    Clive, K.S.4    Patil, R.5    Benavides, L.C.6    Gates, J.D.7    Sears, A.K.8    Stojadinovic, A.9    Ponniah, S.10    Peoples, G.E.11
  • 11
    • 0035116901 scopus 로고    scopus 로고
    • The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
    • Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D and Jaffee EM. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001; 61:880-883.
    • (2001) Cancer Res , vol.61 , pp. 880-883
    • Reilly, R.T.1    Machiels, J.P.2    Emens, L.A.3    Ercolini, A.M.4    Okoye, F.I.5    Lei, R.Y.6    Weintraub, D.7    Jaffee, E.M.8
  • 12
    • 0043136619 scopus 로고    scopus 로고
    • HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
    • Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM and Reilly RT. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol. 2003; 171:2161-2169.
    • (2003) J Immunol , vol.171 , pp. 2161-2169
    • Wolpoe, M.E.1    Lutz, E.R.2    Ercolini, A.M.3    Murata, S.4    Ivie, S.E.5    Garrett, E.S.6    Emens, L.A.7    Jaffee, E.M.8    Reilly, R.T.9
  • 13
    • 0034684659 scopus 로고    scopus 로고
    • CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo
    • den Haan JM, Lehar SM and Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000; 192:1685-1696.
    • (2000) J Exp Med , vol.192 , pp. 1685-1696
    • den Haan, J.M.1    Lehar, S.M.2    Bevan, M.J.3
  • 14
    • 78049427830 scopus 로고    scopus 로고
    • Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
    • Ferris RL, Jaffee EM and Ferrone S. Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010; 28:4390-4399.
    • (2010) J Clin Oncol , vol.28 , pp. 4390-4399
    • Ferris, R.L.1    Jaffee, E.M.2    Ferrone, S.3
  • 19
    • 79251503953 scopus 로고    scopus 로고
    • Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    • Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S and Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011; 117:463-471.
    • (2011) Cancer , vol.117 , pp. 463-471
    • Holmes, J.P.1    Clifton, G.T.2    Patil, R.3    Benavides, L.C.4    Gates, J.D.5    Stojadinovic, A.6    Mittendorf, E.A.7    Ponniah, S.8    Peoples, G.E.9
  • 20
    • 0016842811 scopus 로고
    • Editorial: Measurement of delayed skin-test responses
    • Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med. 1975; 293:501-502.
    • (1975) N Engl J Med , vol.293 , pp. 501-502
    • Sokal, J.E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.